Medicine to Market Summits’ Post

🔬 Biotech News: Pyxis Oncology ADC Trial Results Signal Broader Industry Challenges TL;DR: Pyxis Oncology faces significant stock decline following underwhelming early data from their solid tumor ADC trial. 🔍 Key Impact: This setback highlights the complex landscape of ADC development in oncology, demonstrating the delicate balance between innovation and clinical success. It's a stark reminder of the volatility inherent in biotech drug development. 💡 Strategic Takeaways: • Monitor ADC technology evolution closely • Diversify therapeutic pipeline • Pursue strategic partnerships • Strengthen investor communications • Conduct thorough market analysis pre-trial 📈 Industry Implications: This case reinforces the need for robust risk management and clear stakeholder communication in biotech development programs. 💭 What's your take on ADC development risks? How is your organization balancing innovation with clinical success? Share your insights below. #Biotech #DrugDevelopment #ClinicalTrials #ADC #BiotechStrategy

🔬 Pheon Therapeutics Raises $120M Series B for Novel ADC Development TL;DR: • UK-based Pheon secures major funding led by TCGX Capital • Total ADC sector funding: $2.7B across 57 deals (2022-2024) • Company exploring unique tumor targets, avoiding common pathways • Funding runway extended through 2027 Pheon Therapeutics is making waves in the antibody-drug conjugate (ADC) space with their innovative approach to cancer treatment. Their platform targets novel solid tumor expressions while minimizing impact on healthy cells - a key differentiator in the competitive ADC landscape. The investment round attracted top-tier investors including BVF Partners, Perceptive Advisors, Atlas Venture, and Forbion. This follows their successful $68M Series A in 2022, demonstrating strong market confidence in their technology. CEO Cyrus Mozayeni hints at potential IPO plans, market conditions permitting. The company's three lead candidates are advancing through development, with their most advanced asset leveraging proven ADC components while exploring new territory. This raise reflects the broader momentum in ADC therapeutics, with the sector seeing unprecedented deal activity and acquisitions since 2022. 💭 What's your take on the ADC market's explosive growth? Are we entering a golden age for targeted cancer therapeutics? #Biotech #CancerResearch #ADC #BiotechInvestment #Oncology #intelligencesimplified #pharma #biotech #biodatastudio

🔬 Biotech News: Pyxis Oncology ADC Trial Results Impact Market TL;DR: 📉 Pyxis Oncology experiences significant stock decline following underwhelming initial results from their solid tumor ADC trials. 🔍 Key Implications: • Market reaction underscores volatility in ADC investments • Highlights critical importance of robust clinical data • May influence broader ADC technology sentiment 💡 Strategic Takeaways for Biotech Leaders: • Monitor ADC landscape developments closely • Implement rigorous trial design protocols • Maintain transparent milestone communication • Consider R&D portfolio diversification What are your thoughts on the future of ADC technologies in oncology? Share your insights below. #BiotechNews #Oncology #DrugDevelopment #ClinicalTrials #ADC #pharma #biotech #medicinetomarket

🎯 Join the Innovation in Oncology with BiPER Therapeutics! We are developing a revolutionary drug candidate for gastrointestinal cancers. Our unique approach focuses on the metabolism of cancer cells, addressing unmet medical needs. 🛠️ Support our crowdfunding campaign and be part of the future of oncology: BiPER Therapeutics is seeking to raise €500,000 through convertible bonds to finance essential regulatory toxicology studies. 🔑 Why invest in BiPER Therapeutics? • Recognized innovation: Winner of the Matwin OUI Investor Prize 2021, i-Lab 2022, and Challenges 2023. • Growing market: A global market potential of $2.5 billion per year. • Scientific strength: 7 patents filed, in collaboration with Inserm and CNRS. • Unique position: No direct competitors for gastrointestinal cancers. • International interest: Significant interest from pharmaceutical laboratories and institutional funds. 👉 Join us and invest in the medicine of tomorrow! https://lnkd.in/eGvZHznQ With your support, we can transform oncology care. Thank you for your trust and contribution! #Oncology #Innovation #Biotechnology #Investment #Health #Startup

Araris Biotech AG, with its proprietary conjugation technology and linker-payload platforms to efficiently develop and advance next-generation ADCs, is one of the seven innovative companies listed in the Clarivate Companies to Watch report this year. Araris' drug attachment is simple, site-specific and has the potential to stably accommodate various drug-load combinations without altering the pharmacokinetic profile of the antibody, resulting in ADCs with a high therapeutic window. Why is Araris Biotech a company to watch?      Download the report to discover innovations transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest, here: https://lnkd.in/eCSaAWtu #oncology #cancertreatement #biotech #pharma #companiestowatch

𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 𝐄𝐱𝐩𝐚𝐧𝐝𝐬 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐏𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 𝐰𝐢𝐭𝐡 𝐃𝐫𝐞𝐧 𝐁𝐢𝐨 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 Novartis Novartis has entered a strategic collaboration with Dren Bio Dren Bio, Inc. to develop bispecific antibodies for cancer. This includes a $150 million upfront payment, $25 million equity investment, and up to $2.85 billion in potential milestones. Dren Bio’s platform targets myeloid cells to enhance therapeutic effects and safety. Novartis will handle clinical development, manufacturing, regulatory, and commercialization activities. This partnership adds to Novartis’ recent deals, including acquisitions of Mariana Oncology and a partnership with PeptiDream. #Novartis #Oncology #CancerTreatment #BispecificAntibodies #Biotech #Pharma #ImmunoOncology #ClinicalDevelopment #HealthcareInnovation #DrenBio #Partnerships

📺 Proactive | Interview with Dr Chris Burns    Last week Amplia announced its new research collaboration with Korean drug screening company, Next&Bio.    CEO Dr Chris Burns spoke with Proactive’s Tylah Tully about the Company’s plans to test narmafotinib with a new class of drugs called kRas inhibitors.     Here’s an excerpt:   “kRas is a known oncogene that drives cancer, and we think in time, kRas inhibitors will be quite a big player in terms of treatment of pancreatic cancer and other cancers. So we want to demonstrate that our drugs actually can combine …and make those k RAS inhibitors work better. So there's a huge commercial opportunity for us if we show that there's already good scientific rationale for that.”    Take a look 👉 https://lnkd.in/g8QZjTA6     $ATX #Amplia #cancer #oncology #pancreaticcancer #pharma #innovation  

🔬 Breaking: Boehringer Ingelheim Acquires Circle Pharma's Cancer Program for $607M Key Highlights: • Major acquisition targeting innovative cyclic peptide therapies • Deal focuses on preclinical cancer program • Signals growing value of early-stage oncology assets Why This Matters: The deal reflects a significant shift in big pharma's approach to pipeline building. Major players are increasingly willing to invest heavily in preclinical assets, particularly those leveraging novel therapeutic modalities. Strategic Takeaways: 1. Novel drug modalities are commanding premium valuations 2. Early-stage oncology assets remain highly attractive 3. Innovative therapeutic platforms are driving significant deal flow 💡 For Biotech Leaders: - Review your portfolio for similar partnership opportunities - Consider ramping up R&D in next-gen therapeutics - Evaluate preclinical asset valuations in current market context What's your take on this trend? Are we seeing a shift in how early-stage assets are valued in oncology? Share your thoughts below. #Biotech #Oncology #MergersAndAcquisitions #DrugDevelopment #pharma #biotech #medicinetomarket

The ADC gold rush continues - Elevation Oncology just committed up to $368M for Synaffix BV's technology platform. But there's something particularly intriguing about their HER3 strategy... While MSD / Daiichi Sankyo US have shown "HER3 certainly has legs" with their phase 3 success, Elevation is taking a fundamentally different approach to ADC design. They're betting that the combination of precise conjugation technology and thoughtful payload selection could create meaningful differentiation. The science here is fascinating. Most HER3 ADCs in development use topoisomerase inhibitor payloads, but Elevation's choice of MMAE, combined with Synaffix's site-specific conjugation and polar spacer technologies, suggests they're prioritizing stability and controlled payload delivery. What makes this approach noteworthy: 1. Site-specific conjugation for consistent drug-antibody ratio 2. Novel polar spacer technology for stability 3. MMAE payload diverging from the topo-inhibitor trend 4. Potential for improved therapeutic window Yes, they're behind Merck/Daiichi and BioNTech SE chronologically. But in ADC development, being first isn't always being best - sometimes it's about having the right technology combination. The ADC field isn't just expanding - it's evolving rapidly in sophistication. #ADC #DrugDevelopment #Oncology #BiotechInnovation ------------------- Hi, I'm James - I post about all things immuno-oncology. I am Vice President of Sales at ichorbio (www.ichor.bio), a bulk manufacturer of in vivo antibodies and research biosimilars. If you like my content please reshare with your network and follow me to see more!

Big Pharma News: AbbVie to Acquire Nimble Therapeutics for $200M 💰 AbbVie is set to acquire Nimble Therapeutics, a leader in peptide discovery, for $200 million in cash at closing. This move underscores AbbVie's continued investment in expanding its research capabilities and advancing cutting-edge therapies. With Nimble's platform for discovering constrained peptides, AbbVie aims to enhance its pipeline in areas like oncology, immunology, and beyond. Read more: https://lnkd.in/e4R2cuJt What are your thoughts on the impact of this acquisition on AbbVie's innovation strategy? #BiotechNews #PharmaUpdates #Acquisition #Innovation